MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
The 4 Best-Performing Psychedelic Stocks
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
TSI EDITOR |
2020-10-26
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
TSI EDITOR |
2020-10-22
Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
TSI EDITOR |
2020-10-22
How and Why Psychedelic Drugs Can Conquer The Mental Health Crisis
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
TSI EDITOR |
2020-10-22
Psyched Wellness Ltd. to Commence Trading on the CSE on October 22, 2020
The latest psychedelic drug company to commence public trading is Psyched Wellness.
TSI EDITOR |
2020-10-21
Mind Cure’s New Medtech Platform Is A Critical Puzzle-Piece
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
TSI EDITOR |
2020-10-21
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
TSI EDITOR |
2020-10-21
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
TSI EDITOR |
2020-10-20
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
TSI EDITOR |
10/20/2020
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now